SEGMENT INFORMATION (Tables)

9 Months Ended

Jul. 31, 2019

	For the Nine Months Ended July 31,
	For the Nine Months Ended July 31,
	2019		2018
Net loss:
Cancer Diagnostics	$	(4,024,785)	$	(3,783,854)
Cancer Therapeutics		(4,807,668)		(4,583,070)
Patent licensing		(875,138)		(484,640)
Total	$	(9,707,591)	$	(8,851,564)

Operating costs and expenses excluding non-cash share based compensation expense:
Cancer Diagnostics	$	1,953,760	$	1,692,865
Cancer Therapeutics		2,084,694		1,807,515
Patent licensing		1,070,408		1,266,448
Total	$	5,108,862	$	4,766,828

Operating costs and expenses excluding non-cash share based compensation expense	$	5,108,862	$	4,766,828
Plus non-cash share-based compensation expense		4,902,512		5,227,016
Total operating costs and expenses	$	10,011,374	$	9,993,844

	For the Three Months Ended July 31,
	2019		2018
Net loss:
Cancer Diagnostics	$	(917,363)	$	(2,359,568)
Cancer Therapeutics		(1,203,468)		(2,901,708)
Patent licensing		(45,217)		(332,300)
Total	$	(2,166,048)	$	(5,593,576)

Operating costs and expenses excluding non-cash share based compensation expense:
Cancer Diagnostics	$	507,356	$	569,512
Cancer Therapeutics		801,704		359,006
Patent licensing		44,454		411,453
Total	$	1,353,514	$	1,339,971

Operating costs and expenses excluding non-cash share based compensation expense	$	1,353,514	$	1,339,971
Plus non-cash share-based compensation expense		830,898		4,628,333
Total operating costs and expenses	$	2,184,412	$	5,968,304